GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Net Interest Income (for Banks)

3SBio (HKSE:01530) Net Interest Income (for Banks)


View and export this data going back to 2015. Start your Free Trial

What is 3SBio Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


3SBio (HKSE:01530) Business Description

Industry
Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.
Executives
Blackrock, Inc. 2201 Interest of corporation controlled by you
Lou Jing 2305 Beneficiary of a trust
Jpmorgan Chase & Co. 2502 Approved lending agent
Hsbc Holdings Plc 2302 Custodian
Citic Securities Company Limited 2201 Interest of corporation controlled by you
Citron Pe Associates, L.p. 2201 Interest of corporation controlled by you
Citron Pe Funds Limited 2201 Interest of corporation controlled by you
Citron Pe Holdings Limited 2201 Interest of corporation controlled by you
Cpechina Fund, L.p. 2201 Interest of corporation controlled by you
Cs Sunshine Investment Limited 2101 Beneficial owner
Tmf (cayman) Ltd. 2301 Trustee
Xing Lily
Century Sunshine Limited
Decade Sunshine Limited
Lambda International Limited